ciglitazone has been researched along with Head and Neck Neoplasms in 1 studies
ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.
Head and Neck Neoplasms: Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Human oral cancer CA-9-22 and NA cell lines were treated with the PPAR activators eicosatetraynoic acid (ETYA), 15-deoxy-δ- 12,14-prostaglandin J2 (PG-J2), and the thiazolidinedione, ciglitazone, and evaluated for their ability to functionally activate PPARγ luciferase reporter gene constructs." | 1.46 | Functional activation of PPARγ in human upper aerodigestive cancer cell lines. ( Abu Ghazallah, R; Gaffney, PM; Harris, G; Miller, WA; Ondrey, FG; Wright, SK; Wuertz, BR, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wright, SK | 1 |
| Wuertz, BR | 1 |
| Harris, G | 1 |
| Abu Ghazallah, R | 1 |
| Miller, WA | 1 |
| Gaffney, PM | 1 |
| Ondrey, FG | 1 |
1 other study available for ciglitazone and Head and Neck Neoplasms
| Article | Year |
|---|---|
Functional activation of PPARγ in human upper aerodigestive cancer cell lines.
Topics: Antineoplastic Agents; Arachidonic Acids; Cell Line; Cell Line, Tumor; Cell Proliferation; Gene Expr | 2017 |